Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial
In brief
Azetukalner 25 mg cut monthly focal seizures by a median 53%
In adults with drug-resistant focal epilepsy, monthly seizure frequency fell by a median 53% with 25 mg azetukalner over 12 weeks, compared with 10% on placebo; the 15 mg dose reduced seizures by 35%. Side effects were generally well tolerated, but longer-term safety and whether the reductions persist in routine care remain to be established.
- Journal
- JAMA neurology (Q1)
- Published
- 9 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Jacqueline A French, W Curt LaFrance, Philippe Ryvlin, Eugen Trinka, Vicente Villanueva, Robert Wechsler, et al.
- PMID
- 43002431
- DOI
- 10.1001/jamaneurol.2026.4141
Why clinicians should know about it
- Picked for Neurology (clinical) (top studies of the week, 15 November 2026): Phase 3 randomized trial of a novel focal-seizure treatment
Abstract
IMPORTANCE: Despite more than 30 approved antiseizure medications, many individuals with focal epilepsy continue to experience seizures, indicating a persistent need for novel therapies. OBJECTIVE: To determine efficacy and safety of the novel, potent KV7 channel opener azetukalner for treatment of focal seizures. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, placebo-controlled randomized clinical trial of azetukalner was conducted over a 12-week double-blind period (November 18, 2022, to February 3, 2026) at 138 sites in North America, South America, Europe, and Asia Pacific. Adults with focal epilepsy experiencing 4 or more focal seizures per month despite stable treatment with 1 to 3 antiseizure medications were enrolled. Data were analyzed using a dataset derived from the database lock dated February 26, 2026. INTERVENTIONS: Participants were randomized 1:1:1 to receive placebo or 15 or 25 mg of azetukalner once daily with the evening meal for 12 weeks with no titration period. Participants completing the double-blind period could enter an open-label extension. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was median percentage change from baseline in monthly (28-day) focal seizure frequency during the double-blind period for azetukalner vs placebo. Safety and tolerability were assessed by recording treatment-emergent adverse events, changes in clinical laboratory findings, vital signs, and electrocardiogram. RESULTS: Of 607 adults screened, 374 participants (190 [50.8%] female; mean [SD] age, 40.0 [12.9] years) were enrolled, randomized and treated with placebo (125 participants), 15-mg azetukalner (125 participants), or 25-mg azetukalner (124 participants). Participants had a baseline median (IQR) of 12.75 (7.56 to 32.97) seizures per month and had previously tried and stopped a median (IQR) of 5 (3 to 8) antiseizure medications. Most (336 participants [89.8%]) were receiving 2 to 3 concomitant antiseizure medications. The median (IQR) change from baseline in monthly seizure frequency was -10.4% (-39.1% to 8.3%) for the placebo group, -34.5% (-61.6% to -12.3%) for the 15-mg azetukalner group (P < .001 vs placebo), and -53.2% (-77.2% to -28.8%) for the 25-mg azetukalner group (P < .001 vs placebo). Azetukalner was generally well tolerated, and treatment-emergent adverse events were comparable to those observed in the phase 2b X-TOLE trial. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that azetukalner demonstrated robust, rapid, and durable reductions in seizure frequency with a favorable benefit-risk profile. Treatment with azetukalner resulted in one of the largest median percentage reductions in seizure frequency vs placebo reported to date in patients with drug-resistant epilepsy, supporting azetukalner as a promising novel antiseizure medication with significant opportunity to improve clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05614063.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.